ProQR Therapeutics (NASDAQ:PRQR) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.14) by 35.71 percent. This is a 25 percent increase over losses of $(0.12) per share from the same period last year. The company reported quarterly sales of $10.183 million which beat the analyst consensus estimate of $5.560 million by 83.15 percent. This is a 135.34 percent increase over sales of $4.327 million the same period last year.